Research ArticleClinical Investigation
Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT
Sherrington Li, Andrew Nguyen, William Counter, Nikeith C. John, Jeremiah De Leon, George Hruby, Anthony M. Joshua, Phillip Stricker, Megan Crumbaker, Narjess Ayati, Lyn Chan, Zahra Sabahi, Mina Swiha, Andrew Kneebone, Keith Wong, Victor Liu, Shikha Sharma, Shikha Agrawal and Louise M. Emmett
Journal of Nuclear Medicine August 2024, jnumed.124.267881; DOI: https://doi.org/10.2967/jnumed.124.267881
Sherrington Li
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
Andrew Nguyen
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
2St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
William Counter
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
Nikeith C. John
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
Jeremiah De Leon
3Genesis Cancer Care, Sydney, New South Wales, Australia;
George Hruby
3Genesis Cancer Care, Sydney, New South Wales, Australia;
4Department of Radiation Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia;
5Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia;
Anthony M. Joshua
6Kinghorn Cancer Care Centre, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
7Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
8St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
Phillip Stricker
5Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia;
9Department of Urology, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
10Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; and
Megan Crumbaker
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
2St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
7Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
Narjess Ayati
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
2St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
7Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
Lyn Chan
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
Zahra Sabahi
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
Mina Swiha
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
11Nuclear Medicine Division, Department of Medical Imaging, University of Western Ontario, London, Ontario, Canada
Andrew Kneebone
5Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia;
Keith Wong
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
Victor Liu
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
Shikha Sharma
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
Shikha Agrawal
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
6Kinghorn Cancer Care Centre, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
7Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
Louise M. Emmett
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
2St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
7Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 10
October 1, 2024
Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT
Sherrington Li, Andrew Nguyen, William Counter, Nikeith C. John, Jeremiah De Leon, George Hruby, Anthony M. Joshua, Phillip Stricker, Megan Crumbaker, Narjess Ayati, Lyn Chan, Zahra Sabahi, Mina Swiha, Andrew Kneebone, Keith Wong, Victor Liu, Shikha Sharma, Shikha Agrawal, Louise M. Emmett
Journal of Nuclear Medicine Aug 2024, jnumed.124.267881; DOI: 10.2967/jnumed.124.267881
Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT
Sherrington Li, Andrew Nguyen, William Counter, Nikeith C. John, Jeremiah De Leon, George Hruby, Anthony M. Joshua, Phillip Stricker, Megan Crumbaker, Narjess Ayati, Lyn Chan, Zahra Sabahi, Mina Swiha, Andrew Kneebone, Keith Wong, Victor Liu, Shikha Sharma, Shikha Agrawal, Louise M. Emmett
Journal of Nuclear Medicine Aug 2024, jnumed.124.267881; DOI: 10.2967/jnumed.124.267881
Jump to section
Related Articles
Cited By...
- No citing articles found.